This study compared the hemostatic effects of E 2V/DNG with those of E 2/NOMAC. The duration of total and withdrawal bleeding was significantly lower with the 24/4 regimen than the 21/7 regimen ( p < 0.05).Д® 2 1.5 mg/NOMAC 2.5 mg for 21 days followed by E 2 for 7 days The largest follicular diameter was significantly smaller and mean follicle stimulating hormone levels were significantly lower with the 24/4 regimen than the 21/7 regimen ( p < 0.05).

Ovulation was inhibited with both regimens.Д® 2 1.5 mg/NOMAC 2.5 mg for 24 days followed by E 2 for 4 days NOMAC 2.5 mg for 21 days followed by 7-day pill-free period

The addition of E 2 1.5 mg to NOMAC 2.5 mg resulted in statistically significant increases in E 2 levels and decreases in mean follicle-stimulating hormone and luteinizing hormone levels.Д® 2 5 mg/NOMAC 1.25 mg for 21 days followed by 7-day pill-free periodД® 2 1.5 mg/NOMAC 2.5 mg for 21 days followed by 7-day pill-free period The lowest plasma E 2 levels were observed with NOMAC 2.5 mg. Ovulation was suppressed in all treatment groups.Д® 2 1.5 mg/NOMAC 0.625 mg for 21 days followed by 7-day pill-free period Reductions in follicle size were observed with both treatments, from 19.3 mm to 6.9вЂ“8.2 mm with E 2/NOMAC and from 19.6 mm to 7.4вЂ“10.8 mm with EE/drospirenone.Д®E 30 Ојg/drospirenone 3 mg for 21 days followed by 7-day pill-free period The total number of bleeding days reduced with E 2V/CPA and increased with E 2V/norethisterone.Д® 2V 1 mg/norethisterone 1 mg for 10 days followed by E 2V 2 mg/norethisterone 2 mg for 11 days followed by 7-day pill-free period (not commercially available)Д® 2V 1 mg/CPA 1 mg for 10 days followed by E 2V 2 mg/CPA 2 mg for 11 days followed by 7-day pill-free period (approved only in women >40 years or women 35вЂ“40 years in whom a COC containing EE is not appropriate)Д® 2 1.5 mg/NOMAC 2.5 mg for 24 days followed by 4-day pill-free period In the E 2V/norethisterone group, menstrual blood loss reduced in 40% and increased in 10% of women. Menstrual blood loss reduced in all women in the E 2V/CPA group. Spotting and breakthrough bleeding were significantly more common with natural estrogen than with EE ( p 40 years or women 35вЂ“40 years in whom a COC containing EE is not appropriate)

1981 Д® 2 4 mg/E3 2 mg/norethisterone acetate 3 mg for 21 days followed by 7-day pill-free periodД®E 50 Ојg/norethisterone acetate 3 mg for 21 days followed by 7-day pill-free period The main reasons for discontinuation: amenorrhea and weight gain with Netagen 403 intermenstrual spotting with Netagen 423 nausea and weight gain with Netasyn.Д®E 50 Ојg/norethisterone 3 mg (Netasyn) for 21 days followed by 7-day pill-free period Micronized E 2 4 mg + E3 2 mg/norethisterone 3 mg (Netagen 423) for 21 days followed by 7-day pill-free period Micronized E 2 4 mg/norethisterone 3 mg (Netagen 403) for 21 days followed by 7-day pill-free periodДiscontinuation rates were similar between treatment groups (Netagen 403: n = 39 Netagen 423: n = 31 Netasyn: n = 35)

Nomacs arm